What they were paid
RIGEL PHARMACEUTICALS Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $57,416 | $23,688 | $207,516 | $0 | $288,620 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RIGEL PHARMACEUTICALS INC DEF 14A filed April 3, 2026, accession 0001034842-26-000023, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themNominating/Governance · Scientific and Clinical Trial Advisory Committee
The rest of the RIGEL PHARMACEUTICALS board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Alison L. Hannah, M.D | Independent Director | $165,767 |
| Gregg A. Lapointe | Chair of the Board | $217,767 |
| Jane Wasman, J.D | Independent Director | $172,767 |
| Kamil Ali-Jackson | Independent Director | $167,767 |
| Michael P. Miller | Independent Director | $0 |
| Raul R. Rodriguez | Director | $0 |
| Walter H. Moos, Ph.D | Independent Director | $165,767 |
The full RIGEL PHARMACEUTICALS compensation record
free company briefThis page is one director within RIGEL PHARMACEUTICALS's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat